OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+30.02%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$201M
AUM Growth
+$201M
(+18%)
Cap. Flow
+$6.28M
Cap. Flow
% of AUM
3.13%
Top 10 Holdings %
Top 10 Hldgs %
56.18%
Holding
53
New
13
Increased
15
Reduced
7
Closed
9
Top Buys
| 1 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
$7.84M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$6.21M |
| 3 |
Ocular Therapeutix
OCUL
|
$4.24M |
| 4 |
CytomX Therapeutics
CTMX
|
$2.94M |
| 5 |
ZSAN
Zosano Pharma Corporation
ZSAN
|
$2.38M |
Top Sells
| 1 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$12.4M |
| 2 |
Neurogene
NGNE
|
$3.75M |
| 3 |
MacroGenics
MGNX
|
$3.48M |
| 4 |
Omeros
OMER
|
$2.63M |
| 5 |
Clearside Biomedical
CLSD
|
$2.41M |
Sector Composition
| 1 | Healthcare | 92.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $35.2M | 17.51% | 880,000 | – | – |
|
2
Axogen
AXGN
$743M
| $20.6M | 10.25% | 1,970,000 | – | – |
|
3
FibroGen
FGEN
$47.8M
| $8.13M | 4.05% | 330,000 | – | – |
|
|
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $7.84M | 3.9% | +730,000 | New | +$7.84M |
|
|
CMRX
5
DELISTED
Chimerix, Inc.
CMRX
| $7.75M | 3.86% | 1,215,000 +45,000 | +4% | +$287K |
|
6
Agios Pharmaceuticals
AGIO
$2.19B
| $7.59M | 3.78% | 130,000 | – | – |
|
|
TVRD
7
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $7.08M | 3.52% | 385,000 -90,000 | -19% | -$1.66M |
|
8
Theravance Biopharma
TBPH
$699M
| $6.63M | 3.3% | 180,000 +21,800 | +14% | +$803K |
|
|
IMMU
9
DELISTED
Immunomedics Inc
IMMU
| $6.21M | 3.09% | +960,000 | New | +$6.21M |
|
|
MNTA
10
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $5.87M | 2.92% | 440,000 +110,000 | +33% | +$1.47M |
|
|
11
CytomX Therapeutics
CTMX
$336M
| $5.87M | 2.92% | 340,000 +170,000 | +100% | +$2.94M |
|
12
Codexis
CDXS
$246M
| $5.62M | 2.8% | 1,170,000 | – | – |
|
|
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
| $5.61M | 2.79% | 1,180,000 +20,000 | +2% | +$95K |
|
|
LOXO
14
DELISTED
Loxo Oncology, Inc
LOXO
| $5.47M | 2.72% | 130,000 +5,000 | +4% | +$210K |
|
|
15
Ocular Therapeutix
OCUL
$2.12B
| $5.1M | 2.54% | 550,000 +456,400 | +488% | +$4.24M |
|
|
ADMS
16
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $5.08M | 2.53% | 290,000 +5,000 | +2% | +$87.5K |
|
17
Prothena Corp
PRTA
$441M
| $4.86M | 2.42% | 87,100 +4,600 | +6% | +$257K |
|
|
EGRX
18
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $4.15M | 2.06% | 50,000 | – | – |
|
19
Harrow
HROW
$1.44B
| $3.59M | 1.79% | 860,500 +140,500 | +20% | +$586K |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $3.2M | 1.59% | 45,000 +10,000 | +29% | +$711K |
|
|
NDRM
21
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $3.19M | 1.59% | 120,000 +5,000 | +4% | +$133K |
|
22
Enanta Pharmaceuticals
ENTA
$180M
| $3.08M | 1.53% | 100,000 +10,000 | +11% | +$308K |
|
23
Sangamo Therapeutics
SGMO
$157M
| $3.02M | 1.5% | 581,000 +181,000 | +45% | +$941K |
|
24
PDS Biotechnology
PDSB
$57.8M
| $2.55M | 1.27% | 280,000 | – | – |
|
|
FOMX
25
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.48M | 1.23% | 500,000 +5,000 | +1% | +$24.8K |
|